A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens

被引：28
|
作者：
Castro, Januario E. [1 ,2 ]
Loria, Olivier J. [1 ,2 ]
Aguillon, Robier A. [1 ,2 ]
James, Danelle [1 ,2 ]
Llanos, Cesar A. [1 ,2 ]
Rassenti, Laura [1 ,2 ]
Wood, Brian A. [3 ]
Homlund, Jon T. [3 ]
Kipps, Thomas J. [1 ,2 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Chronic Lymphocyt Leukemia Res Consortium, La Jolla, CA 92093 USA
[3] ASCENTA Therapeut Inc, San Diego, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3119.3119
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3119
引用
收藏
页码：917A / 918A
页数：2
相关论文
共 50 条
  • [41] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [42] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [43] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [44] A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.
    Camacho, Luis H.
    Joyce, Robin
    Brown, Jennifer R.
    Chanan-Khan, Asher
    Amrein, Philip C.
    Assad, Albert
    Carrigan, Marion
    BLOOD, 2009, 114 (22) : 1330 - 1330
  • [45] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [46] A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Wendtner, C. M.
    Mahadevan, D.
    Coutre, S.
    Hillmen, P.
    Stilgenbauer, S.
    Frankfurt, O.
    Bloor, A.
    Bosch, F.
    Furman, R.
    Uharek, L.
    Kimby, E.
    Gobbi, M.
    Dreisback, L.
    Hurd, D.
    Sekeres, M.
    Gribben, J.
    Shah, S.
    Parseval, L. Moutouh-de
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 371 - 372
  • [47] A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
    Danilov, Alexey V.
    Spurgeon, Stephen E.
    Siddiqi, Tanya
    Quinson, Anne-Marie
    Maier, Daniela
    Smith, Dionne
    Brown, Jennifer R.
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1099 - 1105
  • [48] A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
    Alexey V. Danilov
    Stephen E. Spurgeon
    Tanya Siddiqi
    Anne-Marie Quinson
    Daniela Maier
    Dionne Smith
    Jennifer R. Brown
    Investigational New Drugs, 2021, 39 : 1099 - 1105
  • [49] Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
    Cortelezzi, A.
    Sciume, M.
    Liberati, A. M.
    Vincenti, D.
    Cuneo, A.
    Reda, G.
    Laurenti, L.
    Zaja, F.
    Marasca, R.
    Chiarenza, A.
    Gritti, G.
    Orsucci, L.
    Storti, S.
    Angelucci, E.
    Cascavilla, N.
    Gobbi, M.
    Mauro, F. R.
    Morabito, F.
    Fabris, S.
    Piciocchi, A.
    Vignetti, M.
    Neri, A.
    Rossi, D.
    Giannarelli, D.
    Guarini, A.
    Foa, R.
    LEUKEMIA, 2014, 28 (03) : 642 - 648
  • [50] Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
    A Cortelezzi
    M Sciumè
    A M Liberati
    D Vincenti
    A Cuneo
    G Reda
    L Laurenti
    F Zaja
    R Marasca
    A Chiarenza
    G Gritti
    L Orsucci
    S Storti
    E Angelucci
    N Cascavilla
    M Gobbi
    F R Mauro
    F Morabito
    S Fabris
    A Piciocchi
    M Vignetti
    A Neri
    D Rossi
    D Giannarelli
    A Guarini
    R Foà
    Leukemia, 2014, 28 : 642 - 648
12345